Search

Your search keyword '"Quirant Sánchez Bibiana"' showing total 39 results
Start Over Author "Quirant Sánchez Bibiana"
39 results on '"Quirant Sánchez Bibiana"'

1. SARS-CoV-2: una nueva amenaza

Author

López Rodríguez Cristina A., Boigues Pons Marc, Quirant Sánchez Bibiana, Teniente Serra Aina, Climent Martí Joan, and Martínez Cáceres Eva Ma

Subjects
covid-19, pandemia, respuesta inmunitaria, sars-cov-2, Medical technology, R855-855.5
Abstract

Aportar una breve revisión del conocimiento actual sobre el virus SARS-CoV-2, cuya irrupción ha causado un gran impacto en la sociedad a escala mundial.

Published
2020
Full Text
View/download PDF

2. Increased Risk of Myositis-Specific and Myositis-Associated Autoantibodies After COVID-19 Pandemic and Vaccination: A Spanish Multicenter Collaborative Study.

Author

García-Bravo, Laura, Prada, Alvaro, Gutiérrez Larrañaga, María, Espinosa Ros, Eduardo, Almeida González, Delia, Martín Martínez, Dolores, Rodríguez Sánchez, Telesforo, Mingorance Gámez, Carlos Gustavo, Jurado Roger, Aurora, Aguado Álvarez, Rocío, Díaz Luna, María De Las Mercedes, Rodríguez Hernández, Carmen, de la Varga-Martínez, Raquel, López-Cueto, María, Julià Benique, Maria Rosa, San José-Cascón, Miriam, Quirant-Sánchez, Bibiana, Martínez-Chamorro, Alba, Marcaida-Benito, Goitzane, and Timoneda Timoneda, Pilar Teresa

Subjects
COVID-19, COVID-19 vaccines, IDIOPATHIC diseases, SYMPTOMS, MESSENGER RNA
Abstract

Background: Emerging evidence suggests that SARS-CoV-2 infection and vaccines may trigger autoimmune responses in predisposed individuals. Idiopathic inflammatory myopathies (IIMs) are diseases with diverse clinical manifestations, often associated with myositis autoantibodies (MAs). Diagnosing IIM is challenging due to limitations in classification criteria and diagnostic assays. This study aimed to describe the incidence of IIM following SARS-CoV-2 infection or vaccination and compare rates between exposures. Methods: A multicenter observational study was conducted with 788 patients from 11 Spanish referral centers. A total of 1209 autoantibodies including myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs), were analyzed using line blot immunoassay (LIA). Results: The study identified distinct patterns in aminoacyl-tRNA synthetase (ARS) antibody frequencies compared to pre-pandemic periods. Anti-PL-7 was the most prevalent ARS antibody (14.85%), while anti-Jo-1 was less frequent (7.23%). Anti-MDA5, commonly linked to SARS-CoV-2 infection, was detected in 11.68%. ANA positivity was observed in 60.66%, suggesting an autoimmune background. The most frequent diagnoses were anti-synthetase syndrome (ASSD) or IIM-non-ASSD (21.31%), followed by other systemic autoimmune diseases (SAIDs) (13.57%). Among the cohort, 91.13% received at least one dose of a messenger RNA (mRNA) COVID-19 vaccine, with a median of three doses per patient. Patients with prior SARS-CoV-2 infection or heterologous vaccination showed a higher frequency of multiple autoantibody positivity (p < 0.05), reflecting distinct immune signatures. Conclusions: This study provides valuable insights into the autoimmune risks and phenotypes associated with SARS-CoV-2 infection and vaccination, establishing a basis for further research on IIM and its link to MSAs and MAAs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

Author

Sancho-Saldaña, Agustín, primary, Gil-Sánchez, Anna, additional, González-Mingot, Cristina, additional, Peralta, Silvia, additional, Solana, Maria Jose, additional, Torres, Pascual, additional, Juanes, Alba, additional, Quibus, Laura, additional, Ruiz, Emilio, additional, Sanpedro, Eduardo, additional, Quirant-Sánchez, Bibiana, additional, Martínez-Cáceres, Eva, additional, Ramo Tello, Cristina, additional, Presas-Rodríguez, Silvia, additional, García Rubio, Sebatián, additional, Baron, Beatriz Pardiñas, additional, Ramió-Torrentà, Lluís, additional, Sotoca, Javier, additional, González-Suárez, Inés, additional, Eichau, Sara, additional, Prieto-González, José M., additional, Blasco Quilez, Maria Rosario, additional, Sabín-Muñoz, Julia, additional, Sánchez-López, Antonio José, additional, Llorens Calatayud, Gloria, additional, Calles, Carmen, additional, Sempere, Ángel Pérez, additional, Garcés, Moises, additional, Carmona, Olga, additional, Moral, Ester, additional, Hervás, José Vicente, additional, Blanco, Yolanda, additional, Sola-Valls, Nuria, additional, Tellez Lara, Nieves, additional, Forero, Lucía, additional, and Brieva, Luis, additional

Published
2023
Full Text
View/download PDF

9. Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines—Effectiveness in Delta Variant Breakthrough Infections

Author

Fernández-Rivas, Gema, primary, Barallat, Jaume, additional, Quirant-Sánchez, Bibiana, additional, González, Victoria, additional, Doladé, María, additional, Martinez-Caceres, Eva, additional, Piña, Monica, additional, Matllo, Joan, additional, Blanco, Ignacio, additional, and Cardona, Pere-Joan, additional

Published
2022
Full Text
View/download PDF

10. Increased Natural Killer Cells Are Associated with Alcohol Liver Fibrosis and with T Cell and Cytotoxic Subpopulations Change

Author

Zuluaga, Paola, Teniente-Serra, Aina, Fuster, Daniel, Quirant-Sánchez, Bibiana, Hernandez-Rubio, Anna, Martínez Cáceres, Eva María, Muga, Roberto, Zuluaga, Paola, Teniente-Serra, Aina, Fuster, Daniel, Quirant-Sánchez, Bibiana, Hernandez-Rubio, Anna, Martínez Cáceres, Eva María, and Muga, Roberto

Abstract

Natural killer (NK) cells play a therapeutic role in liver fibrosis (LF). We aimed to analyze NK cells in heavy drinkers without cirrhosis or decompensated liver disease and establish correlations with other related subpopulations. Data on sociodemographic characteristics, alcohol consumption, laboratory parameters, and immunophenotyping of NK (CD16 + /CD56 +), T (CD3 +), B (CD19 +), NKT (CD16 + /CD56 + /CD3 +), and cytotoxic (CD3 - CD8 +) cells were collected. Fibrosis-4 (FIB-4) scores were used to compare patients without (FIB-4 < 1.45) and with (FIB-4 > 3.25) advanced LF (ALF). We included 136 patients (76% male) with a mean age of 49 years who had a 15-year alcohol use disorder (AUD) and alcohol consumption of 164 g/day. Patients with ALF (n = 25) presented significantly lower absolute total lymphocyte, T cell, B cell, and NKT cell numbers than patients without LF (n = 50; p < 0.01). However, the NK cells count was similar (208 ± 109 cells/µL vs. 170 ± 105 cells/µL) in both groups. The T cells percentage was lower (80.3 ± 5.6% vs. 77 ± 7%; p = 0.03) and the NK cells percentage was higher (9.7 ± 5% vs. 13 ± 6%; p = 0.02) in patients with ALF than in those without LF. The percentages of NK cells and T cells were inversely correlated in patients without (r = -0.65, p < 0.01) and with ALF (r = −0.64; p < 0.01). Additionally, the NK cells and CD3 - CD8 + cell percentages were positively correlated in patients without (r = 0.87, p < 0.01) and with (r = 0.92; p < 0.01) ALF. Conclusions: Heavy drinkers without decompensated liver disease showed an increase in NK cells related to T cells lymphopenia and an increase in cytotoxic populations. The interaction of NK cells with other subpopulations may modify alcohol-related liver disease progression.

Published
2022

11. Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies

Author

Sancho-Saldaña, Agustín, primary, Gil Sánchez, Anna, additional, Quirant-Sánchez, Bibiana, additional, Nogueras, Lara, additional, Peralta, Silvia, additional, Solana, Maria José, additional, González-Mingot, Cristina, additional, Gallego, Yhovanni, additional, Quibus, Laura, additional, Ramo-Tello, Cristina, additional, Presas-Rodríguez, Silvia, additional, Martínez-Cáceres, Eva, additional, Torres, Pascual, additional, Hervás, José Vicente, additional, Valls, Joan, additional, and Brieva, Luis, additional

Published
2022
Full Text
View/download PDF

15. Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator

Author

Mansilla, María José, primary, González-Larreategui, Iñigo, additional, Figa-Martín, Neus, additional, Barallat, Jaume, additional, Fondelli, Federico, additional, Sellés-Rius, Ares, additional, Quirant-Sánchez, Bibiana, additional, Teniente-Serra, Aina, additional, and Martínez-Cáceres, Eva, additional

Published
2021
Full Text
View/download PDF

18. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave

Author

Barallat, Jaume, primary, Fernández-Rivas, Gema, additional, Quirant-Sánchez, Bibiana, additional, González, Victoria, additional, Doladé, Maria, additional, Martinez-Caceres, Eva, additional, Piña, Monica, additional, Matllo, Joan, additional, Estrada, Oriol, additional, and Blanco, Ignacio, additional

Published
2020
Full Text
View/download PDF

20. Immunological Pattern in IgA Nephropathy

Author

Esteve Cols, Clara, primary, Graterol Torres, Freddzia-Amanda, additional, Quirant Sánchez, Bibiana, additional, Marco Rusiñol, Helena, additional, Navarro Díaz, Maruja Isabel, additional, Ara del Rey, Jordi, additional, and Martínez Cáceres, Eva Mª, additional

Published
2020
Full Text
View/download PDF

21. AB0643 CLINICAL AND ANALYTICAL DESCRIPTION OF A DERMATOMYOSITIS SERIES OF PATIENTS

Author

Mónica Munera-Campos, Jordi Camins-Fàbregas, Anne Riveros, María Aparicio-Espinar, Susana Holgado, Annika Nack, Anahy Brandy-Garcia, Lourdes Mateo, Clara Esteve-Cols, Ivette Casafont-Solé, Águeda Prior-Español, Melania Martínez-Morillo, Quirant-Sánchez Bibiana, Josep Roca, Clara Sangüesa-Gomez, Laia Gifre, Eva Martínez-Cáceres, Isabel Bielsa-Marsol, and Alejandro Olivé

Subjects
030203 arthritis & rheumatology, 0301 basic medicine, medicine.medical_specialty, business.industry, Antisynthetase syndrome, Dermatomyositis, medicine.disease, Gastroenterology, Polymyositis, Pulmonary hypertension, 03 medical and health sciences, FEV1/FVC ratio, 030104 developmental biology, 0302 clinical medicine, DLCO, Internal medicine, Medicine, Complication, business, Pneumonitis
Abstract

Background: Dermatomyositis (DM) is an idiopathic inflammatory myopathy. The recent years has increased its knowledge thanks to best characterization of myositis-specific antibodies that correlate with different clinical phenotypes.with different clinical phenotypes. Objectives: To describe the clinical and analytical features of a series of dermatomyositis: clinical debut, clinical manifestations as well as the treatments received and the evolution of the disease. Methods: Patients diagnosed of dermatomyositis in a tertiary hospital between the years 1978-2018 according to the criteria of Bohan and Peter (1975) and according to Dalakas’ classification criteria (2015). Clinical, analytical and immunological profile data were collected, as well as treatments received and the evolution of the disease. Results: A total of 59 inflammatory myopathies diagnosed between the years 1985 and 2018 were included. 46 were dermatomyositis (78%), 9 polymyositis (15%) and 4 necrotizing myositis (7%). 69% were women and 22% were smokers. Clinic started at 54 ± 17 years. The initial manifestation was pulmonary in 26.7% followed by cutaneous manifestations (24.4%) and the muscular (22.2%), while a 17.8% started skin and muscular manifestations at the same time. 45.5% behaved like a myopathic DM while a 28% as amyopathic DM and antisynthetase syndrome respectively. 38% presented interstitial involvement being the most common non-specific interstitial pneumonitis (76%)followed by usual interstitial pneumonitis (17%). In these patients, DLCO was decreased (mean of 58.9% and 13.2) as well as the FVC (average of 58%, 2.5L). 73.3% presented cutaneous involvement being the most common manifestations the Gottron papules (37.8%) and the heliotrope rash (35.6%), and up to 27% had cuticular affectacion. 64% had muscle involvement, afecting proximal and symmetrical. Neck flexors were affected in a 38% of patients while 20% had dysphagia.Only 3 patients presented dysphonia (7%) and 2 myocarditis Analytical data Conclusion: 80% received corticotherapy at a dose of mg/kg/day and 20% required high doses of metilprednisolone due to muscular involvement or pulmonary. 18% immunoglobulins and 11% cyclophosphamide. As maintenance 80% received disease modifiying antirheumatic drug in addition to corticosteroid therapy in descending doses (azathioprine 22%, dolquine 15%, tacrolimus 13.3%, rituximab 11%) due to muscle (29.9%), cutaneous (24.4%) and pulmonary involvement (22.2%). As complications, 2 cases of the syndrome were registered hemophagocytic Virtually all patients they presented pulmonary hypertension (mean 34 ± 12 mmHg). 5 patients (11.1%) were diagnosed with neoplasia, two of them after the diagnosis of DM. The mortality was 24%. 3 patients died due to a rapidly progressive pneumonitis, another 2 due to alveolar hemorrhage and three of them due to complication of the neoplastic disease. Dermatomyositis occurs in a variable way, with predominance of pulmonary, skin and muscle manifestations. They require corticotherapy and immunosuppressive treatment for maintenance, even so, mortality is high. Disclosure of interests: None declared

Published
2019
Full Text
View/download PDF

22. Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration

Author

Willekens, Barbara, primary, Presas-Rodríguez, Silvia, additional, Mansilla, MJ, additional, Derdelinckx, Judith, additional, Lee, Wai-Ping, additional, Nijs, Griet, additional, De Laere, Maxime, additional, Wens, Inez, additional, Cras, Patrick, additional, Parizel, Paul, additional, Van Hecke, Wim, additional, Ribbens, Annemie, additional, Billiet, Thibo, additional, Adams, Geert, additional, Couttenye, Marie-Madeleine, additional, Navarro-Barriuso, Juan, additional, Teniente-Serra, Aina, additional, Quirant-Sánchez, Bibiana, additional, Lopez-Diaz de Cerio, Ascensión, additional, Inogés, Susana, additional, Prosper, Felipe, additional, Kip, Anke, additional, Verheij, Herman, additional, Gross, Catharina C, additional, Wiendl, Heinz, additional, Van Ham, Marieke (SM), additional, Ten Brinke, Anja, additional, Barriocanal, Ana Maria, additional, Massuet-Vilamajó, Anna, additional, Hens, Niel, additional, Berneman, Zwi, additional, Martínez-Cáceres, Eva, additional, Cools, Nathalie, additional, and Ramo-Tello, Cristina, additional

Published
2019
Full Text
View/download PDF

24. Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment

Author

Quirant-Sánchez, Bibiana, primary, Presas-Rodriguez, Silvia, additional, Mansilla, María José, additional, Teniente-Serra, Aina, additional, Hervás-García, José V., additional, Brieva, Luis, additional, Moral-Torres, Ester, additional, Cano, Antonio, additional, Munteis, Elvira, additional, Navarro-Barriuso, Juan, additional, Martínez-Cáceres, Eva M., additional, and Ramo-Tello, Cristina, additional

Published
2019
Full Text
View/download PDF

27. Tolerogenic dendritic cell-based treatment in multiple sclerosis (MS): Interim results of two phase I clinical trials. (P3.2-047)

Author

Presas-Rodríguez, Silvia, primary, Willekens, Barbara, additional, Mansilla, M José, additional, Derdelinckx, Judith, additional, Lee, Wai Ping, additional, Navarro-Barriuso, Juan, additional, Teniente-Serra, Aina, additional, Quirant-Sánchez, Bibiana, additional, Nijs, Griet, additional, De Laere, Maxime, additional, Wens, Inez, additional, Cras, Patrick, additional, Parizel, M Paul, additional, Van Hecke, Wim, additional, Ribbens, Annemie, additional, Adams, Geert, additional, Couttenye, Marie Madeleine, additional, Verheij, Herman, additional, Kip, Anke, additional, de Cerio, Ascensión López-Díaz, additional, Inoges, Susana, additional, Prosper, Felipe, additional, Gross, Catharina, additional, Wiendl, Heinz, additional, van Ham, Marieke, additional, Brinke, Anja Ten, additional, Barriocanal-Barriocanal, Ana Maria, additional, Massuet-Vilamajo, Anna, additional, Hens, Niel, additional, Berneman, Zwi, additional, Martínez-Cáceres, Eva M., additional, Cools, Nathalie, additional, and Ramo-Tello, Cristina, additional

Published
2019
Full Text
View/download PDF

29. Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional Hyporesponsiveness.

Author

Navarro-Barriuso, Juan, Mansilla, María José, Quirant-Sánchez, Bibiana, Teniente-Serra, Aina, Ramo-Tello, Cristina, and Martínez-Cáceres, Eva M.

Subjects
T cells, DENDRITIC cells, CELL cycle, CHOLECALCIFEROL, VITAMINS
Abstract

The use of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most robust approaches due to their immune regulatory properties, which are currently being tested in clinical trials. However, the mechanisms that vitD3-tolDC trigger for the induction of tolerance remain elusive. For this reason, we performed a full phenotypical, functional, and transcriptomic characterization of T cells upon their interaction with autologous, antigen-specific vitD3-tolDC. We observed a strong antigen-specific reduction of T cell proliferation, combined with a decrease in the relative prevalence of TH1 subpopulations and IFN- γ production. The analysis of the transcriptomic profile of T CD4+ cells evidenced a significant down-modulation of genes involved in cell cycle and cell response to mainly pro-inflammatory immune-related stimuli, highlighting the role of JUNB gene as a potential biomarker of these processes. Consequently, our results show the induction of a strong antigen-specific hyporesponsiveness combined with a reduction on the TH1 immune profile of T cells upon their interaction with vitD3-tolDC, which manifests the regulatory properties of these cells and, therefore, their therapeutic potential in the clinic. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

Author

Quirant‐Sánchez, Bibiana, primary, Hervás‐García, José V., additional, Teniente‐Serra, Aina, additional, Brieva, Luis, additional, Moral‐Torres, Ester, additional, Cano, Antonio, additional, Munteis, Elvira, additional, Mansilla, María J., additional, Presas‐Rodriguez, Silvia, additional, Navarro‐Barriuso, Juan, additional, Ramo‐Tello, Cristina, additional, and Martínez‐Cáceres, Eva M., additional

Published
2018
Full Text
View/download PDF

32. Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin

Author

Navarro-Barriuso, Juan, Mansilla, María José, Naranjo-Gómez, Mar, Sánchez-Pla, Alex, Quirant-Sánchez, Bibiana, Teniente-Serra, Aina, Ramo-Tello, Cristina, Martínez-Cáceres, Eva M., Navarro-Barriuso, Juan, Mansilla, María José, Naranjo-Gómez, Mar, Sánchez-Pla, Alex, Quirant-Sánchez, Bibiana, Teniente-Serra, Aina, Ramo-Tello, Cristina, and Martínez-Cáceres, Eva M.

Abstract

Tolerogenic dendritic cell (tolDC)-based therapies have become a promising approach for the treatment of autoimmune diseases by their potential ability to restore immune tolerance in an antigen-specific manner. However, the broad variety of protocols used to generate tolDC in vitro and their functional and phenotypical heterogeneity are evidencing the need to find robust biomarkers as a key point towards their translation into the clinic, as well as better understanding the mechanisms involved in the induction of immune tolerance. With that aim, in this study we have compared the transcriptomic profile of tolDC induced with either vitamin D3 (vitD3-tolDC), dexamethasone (dexa-tolDC) or rapamycin (rapa-tolDC) through a microarray analysis in 5 healthy donors. The results evidenced that common differentially expressed genes could not be found for the three different tolDC protocols. However, individually, CYP24A1, MUCL1 and MAP7 for vitD3-tolDC; CD163, CCL18, C1QB and C1QC for dexa-tolDC; and CNGA1 and CYP7B1 for rapa-tolDC, constituted good candidate biomarkers for each respective cellular product. In addition, a further gene set enrichment analysis of the data revealed that dexa-tolDC and vitD3-tolDC share several immune regulatory and anti-inflammatory pathways, while rapa-tolDC seem to be playing a totally different role towards tolerance induction through a strong immunosuppression of their cellular processes.

Published
2018

33. Towards a dendritic cell-based vaccine for the treatment of multiple sclerosis (MS): interim safety data of the first dose cohort of the MS-tolDC phase I clinical trial

Author

Cools, Nathalie, primary, Presas-Rodríguez, Silvia, additional, Mansilla, Maria José, additional, Derdelinckx, Judith, additional, Lee, Wai Ping, additional, Nijs, Griet, additional, De Laere, Maxime, additional, Wens, Inez, additional, Cras, Patrick, additional, Parizel, Paul, additional, Van Hecke, Wim, additional, Ribbens, Annemie, additional, Adams, Geert, additional, Couttenye, Marie-Madeleine, additional, Navarro-Barriuso, Juan, additional, Teniente-Serra, Aina, additional, Quirant-Sánchez, Bibiana, additional, Lopez-diaz De Cerio, Ascension, additional, Inogés, Susana, additional, Prosper, Felipe, additional, Gross, Catharina, additional, Wiendl, Heinz, additional, Van Ham, S. Marieke, additional, Ten Brinke, Anja, additional, Verheij, Herman, additional, Kip, Anke, additional, Barriocanal, Ana Marian, additional, Massuet-Vilamajó, Anna, additional, Hens, Niel, additional, Berneman, Zwi, additional, Martínez-Cáceres, Eva, additional, Ramo-Tello, Cristina, additional, and Willekens, Barbara, additional

Published
2018
Full Text
View/download PDF

34. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients

Author

Puñet-Ortiz, Joan, primary, Hervás-García, José Vicente, additional, Teniente-Serra, Aina, additional, Cano-Orgaz, Antonio, additional, Mansilla, Maria José, additional, Quirant-Sánchez, Bibiana, additional, Navarro-Barriuso, Juan, additional, Fernández-Sanmartín, Marco A., additional, Presas-Rodríguez, Silvia, additional, Ramo-Tello, Cristina, additional, and Martínez-Cáceres, Eva María, additional

Published
2017
Full Text
View/download PDF

35. Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment.

Author

Quirant-Sánchez, Bibiana, Presas-Rodriguez, Silvia, Mansilla, María José, Teniente-Serra, Aina, Hervás-García, José V., Brieva, Luis, Moral-Torres, Ester, Cano, Antonio, Munteis, Elvira, Navarro-Barriuso, Juan, Martínez-Cáceres, Eva M., and Ramo-Tello, Cristina

Subjects
*LYMPHOCYTE subsets, *THERAPEUTICS, *MULTIPLE sclerosis, *BISOPROLOL, *T cells
Abstract

Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n=22) or fingolimod (n=44) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1CM cells (relapsed: 11.60±4.17%vs. nonrelapsed: 9.25±3.17%, p<0.05) and Th1Th17CM cells (relapsed: 15.65±6.15%vs. nonrelapsed: 10.14±4.05%, p<0.01) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17CM (CD4+CCR7+CD45RA-CCR6+CXCR3+) cells>11.48% had a 50% relapse-free survival compared to patients with Th1Th17CMcells<11.48% whose relapse-free survival was 88% (p=0.013, log-rank test). Additionally, a high percentage of Th1Th17CM cells was also found in patients with MRI activity (MRI activity: 14.02±5.87%vs. no MRI activity: 9.82±4.06%, p<0.01). Our results suggest that the percentage of Th1Th17CM lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

38. Diagnostic value of different anti-citrullinated peptides antibodies in rheumatoid arthritis.

Author

de Arrizabaleta, Estíbaliz Ruiz-Ortiz, Grados-Cánovas, Dolors, Teniente-Serra, Aina, García-López, Virginia, Quirant-Sánchez, Bibiana, Holgado, Susana, Olivé, Alejandro, Pujol-Borrell, Ricardo, and Martínez-Cáceres, Eva

Subjects
RHEUMATOID arthritis, PEPTIDES
Abstract

An abstract of the conference paper "Diagnostic value of different anti-citrullinated peptides antibodies in rheumatoid arthritis," by several researchers including, Aina Teniente-Serra, Susana Holgado, and Ricardo Pujol-Borrell is presented.

Published
2011
Full Text
View/download PDF

39. Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4 + Cells Towards a Functional Hyporesponsiveness.

Author

Navarro-Barriuso J, Mansilla MJ, Quirant-Sánchez B, Teniente-Serra A, Ramo-Tello C, and Martínez-Cáceres EM

Subjects
Gene Expression Profiling, Humans, Immune Tolerance immunology, Th1 Cells immunology, Transcriptome immunology, Cholecalciferol pharmacology, Dendritic Cells immunology, Immune Tolerance drug effects, Transcriptome drug effects
Abstract

The use of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most robust approaches due to their immune regulatory properties, which are currently being tested in clinical trials. However, the mechanisms that vitD3-tolDC trigger for the induction of tolerance remain elusive. For this reason, we performed a full phenotypical, functional, and transcriptomic characterization of T cells upon their interaction with autologous, antigen-specific vitD3-tolDC. We observed a strong antigen-specific reduction of T cell proliferation, combined with a decrease in the relative prevalence of T H 1 subpopulations and IFN- γ production. The analysis of the transcriptomic profile of T CD4 + cells evidenced a significant down-modulation of genes involved in cell cycle and cell response to mainly pro-inflammatory immune-related stimuli, highlighting the role of JUNB gene as a potential biomarker of these processes. Consequently, our results show the induction of a strong antigen-specific hyporesponsiveness combined with a reduction on the T H 1 immune profile of T cells upon their interaction with vitD3-tolDC, which manifests the regulatory properties of these cells and, therefore, their therapeutic potential in the clinic., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Navarro-Barriuso, Mansilla, Quirant-Sánchez, Teniente-Serra, Ramo-Tello and Martínez-Cáceres.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results